Chinese Traditional and Herbal Drugs
|
2025, 56(9): 3203-3221
Screening of blood-absorbed constituents against Alzheimer’s disease based on prescription-syndrome-disease association
Full
GUO Pengfei1,2, JIANG Mengmeng1,2, HU Shengquan1,2, JIANG Qianqian1,2, LI Limin1,2, WU Junhong1, MA Yucui1, WU Zhengzhi1,2,3
Affiliations
1 The First Affiliated Hospital of Shenzhen University, Shenzhen Institute of Translational Medicine, Shenzhen 518035, China;
2 Wu Zhengzhi Academician Workstation, Ningbo College of Health Sciences, Ningbo 315800, China;
3 Hunan University of Traditional Chinese Medicine, Changsha 410073, China
doi: 10.7501/j.issn.0253-2670.2025.09.018
Outline
Objective This study aims to screen biomarkers for Alzheimer’s disease (AD), elucidate its pathogenesis, and explore potential therapeutic targets and blood-absorbed constituents (BACs) by integrating network inference algorithms, machine learning, drug-likeness evaluation, molecular docking, and molecular dynamics simulations. Methods Classical TCM formulas containing BACs were screened based on the database of constituents absorbed into the blood and metabolites of traditional Chinese medicine (DCABM-TCM) and the corresponding syndromes and their targets were retrieved from the from syndrome ontology to network-based evaluation of syndrome ontology and formula database (SoFDA). The weighted signed directed tensor network-based inference (wSDTNBI) algorithm was used to predict BACs targets. Differential expressed genes (DEGs) related to AD were identified by mining the GEO database. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed to explore the biological processes and pathways associated with up- and down-regulated DEGs. Core AD genes were screened using the least absolute shrinkage and selection operator (LASSO), support vector machine-recursive feature elimination (SVM-RFE), protein-protein interaction (PPI) network analysis, and text mining. Candidate BACs were further filtered using pan-assay interference compounds (PAINS), Lipinski’s Rule of Five (Ro5), and Rule of Three (Ro3), followed by molecular docking. Results First, a total of 10 classical TCM formulas containing 94 BACs and corresponding to 15 syndromes were selected from 193 formulas. A total of 1 520 syndrome-related genes and 552 BAC targets were predicted. Additionally, 528 up-regulated and 697 down-regulated DEGs targeted by syndromes were identified. Enrichment analysis revealed that these DEGs were primarily involved in biological processes such as positive regulation of gene expression, neuronal anti-apoptosis, and synaptic function, and were significantly enriched in pathways such as phosphatidylinositol 3-kinase (PI3K)-protein kinase B signaling pathway (Akt) signaling, focal adhesion, and AD pathways. The BACs-DEGs-AD network indicated that up- and down-regulated DEGs could target 90 and 74 BACs, respectively, associated with nine syndromes. PPI network analysis identified five core AD genes with high degrees: beta-2 adrenergic receptor (ADRB2), substance-P receptor (TACR1), prostaglandin G/H synthase 2 (PTGS2), serine protease HTRA1A, and metabotropic glutamate receptor 1 (GRM1). Drug-likeness evaluation screened 22 candidate BACs, 11 of which were pharmacologically validated to have anti-AD activity. Molecular docking results showed that unii-x87dcb9gst exhibited superior comprehensive binding energy with the five core AD genes compared to marketed drugs such as donepezil, galantamine, and rivastigmine. Finally, molecular dynamics simulations further confirmed the stable binding of unii-x87dcb9gst to the acetylcholinesterase (AChE) complex. Conclusion This study identified AD biomarkers through multimodal algorithms and revealed AD-related biological processes and signaling pathways through enrichment analysis, providing molecular insights into the interaction mechanisms between TCM syndromes and AD genes. Additionally, unii-x87dcb9gst, screened as a candidate BAC from classical TCM formulas, may serve as a potential therapeutic agent for AD. This research not only offers a multidimensional understanding of AD pathogenesis but also establishes an innovative biomarker screening system and research paradigm for anti-AD drug development.
Alzheimer’s disease
/
formulas
/
syndromes
/
constituents absorbed into blood
/
network inference algorithms
/
machine learning
/
molecular docking
/
molecular dynamics simulations
/
unii-x87dcb9gst
郭鹏飞, 姜孟孟, 胡胜全, 姜倩倩, 李利民, 吴俊红, 马玉翠, 吴正治.
基于方剂-证候-疾病关联的抗阿尔茨海默病可入血成分的筛选.
中草药,
2025
, 56
(9)
: 3203
-3221
.
DOI: 10.7501/j.issn.0253-2670.2025.09.018
GUO Pengfei, JIANG Mengmeng, HU Shengquan, JIANG Qianqian, LI Limin, WU Junhong, MA Yucui, WU Zhengzhi.
Screening of blood-absorbed constituents against Alzheimer’s disease based on prescription-syndrome-disease association[J].
Chinese Traditional and Herbal Drugs,
2025
, 56
(9)
: 3203
-3221
.
DOI: 10.7501/j.issn.0253-2670.2025.09.018
Year 2025 volume 56 Issue 9
43
8
Cite this Article
BibTeX
Article Info
doi: 10.7501/j.issn.0253-2670.2025.09.018
- Receive Date:2024-12-16
- Online Date:2026-11-13